While the Trump administration’s Schedule III order may have swept national headlines on April 23, the follow-up dissemination of the order’s impacts was what cannabis-specific readers cared most about this month.
A Q&A with Brian Vicente, a founding partner at Colorado law firm Vicente LLP, in which he broke down Section 280E tax relief, a new DEA registration process and an accelerated administrative hearing – and other big things about Schedule III that some haven’t thought of – took the spotlight as the No. 1 most-read article in Cannabis Business Times in April.
“It is the biggest thing that has happened in decades of federal cannabis policy,” Vicente told CBT contributor David Downs. “I think this is a force multiplier. I think we are going to see concrete advancement on medical, and we’re also going to see an acceleration of the recreational movement in this country now that you have conservatives and the conservative GOP leader of the country coming out and saying, ‘Hey, there’s medical value here.’”
CBT’s coverage of the breaking news of Acting Attorney General Todd Blanche’s Schedule III order, meanwhile, landed in the No. 4 spot this month, getting pushed by other rescheduling-related stories.
In the No. 2 spot was a piece on Trump signing an executive order five days earlier, directing his administration to accelerate medical research into the therapeutic benefits of psychedelic drugs, in which he paused to plead with his administration to “please” get cannabis rescheduling done and stop “slow-walking” the process.
And a post-rescheduling reactions roundup of 50 industry stakeholders, from cannabis business executives, coalitions and trade groups to advocates, lawmakers, lawyers, service providers and financial experts, took the No 3 spot.
Don’t miss out on the rest of our Top 10 stories from April 2026.
